Medicated Skin Products Market in Pakistan to 2014 (OTC Healthcare)
Book Details
Author(s)Datamonitor
PublisherMarketResearch.com
ISBN / ASINB004VCFROM
ISBN-13978B004VCFRO8
AvailabilityAvailable for download now
MarketplaceUnited States 🇺🇸
Description
Introduction
This databook provides key data and information on the Medicated Skin Products Market in Pakistan (OTC Healthcare). This report is a comprehensive resource for market, category and segment level data including value, volume, distribution share and company & brand share. This report also provides expenditure and consumption data for the historic and forecast periods.
Scope
The medicated skin products category was valued at PKR436.4m ($6.2m) in 2009, representing a CAGR of 7.3% since 2004.
By the end of 2014, the medicated skin products category will be worth PKR572.4m ($8.1m), with an expected CAGR of 5.6% between 2009 and 2014.
The medicated skin products market was led by anti-fungals (representing 34.3% of the total value) followed by anti-bacterials and acne treatments, with a 26.9% and 21.9% market share, respectively. Disinfectants and other medicated skin products constitute the remaining segments with a 9.8% and 7.2% market share, respectively.
Reckitt Benckiser PLC is the market leader with a 19.1% share of the market.
Reasons to Purchase
This databook provides key data and information on the Medicated Skin Products Market in Pakistan (OTC Healthcare). This report is a comprehensive resource for market, category and segment level data including value, volume, distribution share and company & brand share. This report also provides expenditure and consumption data for the historic and forecast periods.
Scope
- Market,category and segment level information on value, volume, and expenditure & consumption, with historic (2003-2008) and forecast (2009-2013) data
- Category level company and brand share as well as distribution share information for 2007 and 2008
The medicated skin products category was valued at PKR436.4m ($6.2m) in 2009, representing a CAGR of 7.3% since 2004.
By the end of 2014, the medicated skin products category will be worth PKR572.4m ($8.1m), with an expected CAGR of 5.6% between 2009 and 2014.
The medicated skin products market was led by anti-fungals (representing 34.3% of the total value) followed by anti-bacterials and acne treatments, with a 26.9% and 21.9% market share, respectively. Disinfectants and other medicated skin products constitute the remaining segments with a 9.8% and 7.2% market share, respectively.
Reckitt Benckiser PLC is the market leader with a 19.1% share of the market.
Reasons to Purchase
- Develop business strategies by understanding the quantitative trends within the Medicated Skin Products Market in Pakistan (OTC Healthcare)
- Design effective marketing and sales strategies by identifying key market categories and segments
- Identify key players within the market to plan lucrative M&A, partnerships and agreements

